Results 301 to 310 of about 6,578,993 (340)
Some of the next articles are maybe not open access.
The Lancet Oncology, 2019
BACKGROUND Belantamab mafodotin (GSK2857916), an immunoconjugate targeting B-cell maturation antigen, showed single-agent activity in the phase 1 DREAMM-1 study in heavily pre-treated patients with relapsed or refractory multiple myeloma.
S. Lonial +37 more
semanticscholar +1 more source
BACKGROUND Belantamab mafodotin (GSK2857916), an immunoconjugate targeting B-cell maturation antigen, showed single-agent activity in the phase 1 DREAMM-1 study in heavily pre-treated patients with relapsed or refractory multiple myeloma.
S. Lonial +37 more
semanticscholar +1 more source
Medical Clinics of North America, 1984
Multiple myeloma is a malignant neoplasm of plasma cells involving bone and bone marrow, frequently leading to extensive skeletal destruction, bone marrow failure, renal dysfunction, and problems related to the monoclonal myeloma proteins. Vigilant supportive care and effective chemotherapy can prolong survival and improve the quality of life in most ...
openaire +2 more sources
Multiple myeloma is a malignant neoplasm of plasma cells involving bone and bone marrow, frequently leading to extensive skeletal destruction, bone marrow failure, renal dysfunction, and problems related to the monoclonal myeloma proteins. Vigilant supportive care and effective chemotherapy can prolong survival and improve the quality of life in most ...
openaire +2 more sources
The Lancet, 2020
BACKGROUND Lenalidomide and bortezomib frontline exposure has raised a growing need for novel treatments for patients with relapsed or refractory multiple myeloma.
M. Dimopoulos +10 more
semanticscholar +1 more source
BACKGROUND Lenalidomide and bortezomib frontline exposure has raised a growing need for novel treatments for patients with relapsed or refractory multiple myeloma.
M. Dimopoulos +10 more
semanticscholar +1 more source
The Lancet, 2019
BACKGROUND Isatuximab is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action.
M. Attal +115 more
semanticscholar +1 more source
BACKGROUND Isatuximab is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action.
M. Attal +115 more
semanticscholar +1 more source
Current Treatment Options in Oncology, 2000
Multiple myeloma (MM) is an incurable plasma cell dyscrasia that remains fatal. Despite efforts over the past 3 to 4 decades, the median survival of patients with MM does not exceed 3 to 4 years. Although patients receiving combination chemotherapy have higher response rates compared with those receiving oral melphalan and prednisolone, they have no ...
N, Raje, K C, Anderson
openaire +2 more sources
Multiple myeloma (MM) is an incurable plasma cell dyscrasia that remains fatal. Despite efforts over the past 3 to 4 decades, the median survival of patients with MM does not exceed 3 to 4 years. Although patients receiving combination chemotherapy have higher response rates compared with those receiving oral melphalan and prednisolone, they have no ...
N, Raje, K C, Anderson
openaire +2 more sources
Seminars in Oncology Nursing, 1996
To review the epidemiology, pathogenesis, clinical features, diagnosis, treatment, and nursing management of multiple myeloma.Review articles, research studies, and book chapters related to multiple myeloma.Despite insights into the immunobiology of multiple myeloma and the advances in intensive therapy and supportive care, multiple myeloma remains an ...
openaire +2 more sources
To review the epidemiology, pathogenesis, clinical features, diagnosis, treatment, and nursing management of multiple myeloma.Review articles, research studies, and book chapters related to multiple myeloma.Despite insights into the immunobiology of multiple myeloma and the advances in intensive therapy and supportive care, multiple myeloma remains an ...
openaire +2 more sources
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
The Journal of the National Comprehensive Cancer Network, 2020Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. This manuscript discusses the management of patients with solitary plasmacytoma, smoldering multiple myeloma, and ...
Shaji K. Kumar +28 more
semanticscholar +1 more source
Current Opinion in Oncology, 1994
The mortality associated with multiple myeloma is due to the progressive accumulation of a clonal population of plasma cells in the bone marrow. Tumor cells may also be found in the blood and other extramedullary sites, especially in the terminal stages of the disease.
M V, Seiden, K C, Anderson
openaire +2 more sources
The mortality associated with multiple myeloma is due to the progressive accumulation of a clonal population of plasma cells in the bone marrow. Tumor cells may also be found in the blood and other extramedullary sites, especially in the terminal stages of the disease.
M V, Seiden, K C, Anderson
openaire +2 more sources
The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape
Nature Immunology, 2021M. D. de Jong +15 more
semanticscholar +1 more source